文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

玻璃体内注射康柏西普治疗伴有隐匿性脉络膜新生血管的慢性中心性浆液性脉络膜视网膜病变:一项基于多模式眼科成像的回顾性临床研究

Intravitreal conbercept for chronic central serous chorioretinopathy with occult CNV: a retrospective clinical study based on multimodal ophthalmic imaging.

作者信息

Wang Suyu, Li Jiajun, Yan Zhipeng, Jiang Qin, Li Keran

机构信息

Department of Ophthalmology, The Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China.

出版信息

Front Med (Lausanne). 2025 Mar 25;12:1550543. doi: 10.3389/fmed.2025.1550543. eCollection 2025.


DOI:10.3389/fmed.2025.1550543
PMID:40201323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11975556/
Abstract

PURPOSE: This study aimed to evaluate the therapeutic efficacy and safety of intravitreal conbercept in patients with chronic central serous chorioretinopathy (cCSC) complicated by occult choroidal neovascularization (CNV), and to explore its potential in improving visual function and various ophthalmic parameters. METHODS: This retrospective, longitudinal, comparative study included 50 patients diagnosed with cCSC and occult CNV. Patients underwent intravitreal conbercept injections and were monitored over a six-month period. Comprehensive ophthalmic evaluation included best-corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF) status, subfoveal choroidal thickness (SFCT), and optical coherence tomography angiography (OCTA). OCTA parameters such as foveal avascular zone (FAZ) area and CNV lesion characteristics were analyzed pre- and post-treatment. Patients were categorized based on changes in CNV lesion size to identify prognostic factors influencing treatment response. RESULTS: Significant improvements were observed in mean BCVA from baseline (0.78 ± 0.50 vs. 0.32 ± 0.31,  < 0.01) in all 50 eyes of the patients, except for one eye. Additionally, there were significant improvements in CMT, SRF status, SFCT, FAZ area, and CNV lesion size post-treatment ( < 0.05). Pearson correlation analysis indicated a positive correlation between baseline BCVA and CMT ( = 0.3615,  = 0.0116). Changes in BCVA post-treatment correlated with alterations in CMT, SRF diameter, and CNV lesion size. Patients with a favorable treatment response had significantly lower baseline CMT (312.17 ± 57.39 vs. 428.86 ± 114.54,  < 0.05) and CNV vessel diameter (17.46 ± 2.72 vs. 24.84 ± 4.02,  < 0.01) compared to those with unfavorable responses. CONCLUSION: Intravitreal conbercept injection was found to be safe and effective in improving BCVA and various ophthalmic parameters in patients with cCSC complicated by occult CNV, with no significant adverse effects observed during the study period. Baseline CMT, SRF diameter, CNV lesion size, and mean CNV vessel diameter were identified as valuable indicators for assessing treatment response and prognosis. These findings provide important insights for the clinical management and prognostic evaluation of cCSC patients with occult CNV, highlighting the utility of multimodal imaging in assessing treatment outcomes.

摘要

目的:本研究旨在评估玻璃体内注射康柏西普治疗慢性中心性浆液性脉络膜视网膜病变(cCSC)合并隐匿性脉络膜新生血管(CNV)患者的疗效和安全性,并探讨其在改善视功能和各项眼科参数方面的潜力。 方法:本回顾性、纵向、对照研究纳入了50例诊断为cCSC合并隐匿性CNV的患者。患者接受玻璃体内康柏西普注射,并在6个月内进行监测。综合眼科评估包括最佳矫正视力(BCVA)、中心黄斑厚度(CMT)、视网膜下液(SRF)状态、黄斑中心凹下脉络膜厚度(SFCT)以及光学相干断层扫描血管造影(OCTA)。分析治疗前后OCTA参数,如黄斑无血管区(FAZ)面积和CNV病变特征。根据CNV病变大小的变化对患者进行分类,以确定影响治疗反应的预后因素。 结果:除1只眼外,所有50只患眼中患者的平均BCVA较基线均有显著改善(0.78±0.50 vs. 0.32±0.31,P<0.01)。此外,治疗后CMT、SRF状态、SFCT、FAZ面积和CNV病变大小均有显著改善(P<0.05)。Pearson相关分析表明,基线BCVA与CMT呈正相关(r=0.3615,P=0.0116)。治疗后BCVA的变化与CMT、SRF直径和CNV病变大小的改变相关。治疗反应良好的患者与反应不佳的患者相比,基线CMT显著更低(312.17±57.39 vs. 428.86±114.54,P<0.05),CNV血管直径也显著更低(17.46±2.72 vs. 24.84±4.02,P<0.01)。 结论:玻璃体内注射康柏西普被发现对于改善cCSC合并隐匿性CNV患者的BCVA和各项眼科参数是安全有效的,在研究期间未观察到显著不良反应。基线CMT、SRF直径、CNV病变大小和平均CNV血管直径被确定为评估治疗反应和预后的有价值指标。这些发现为cCSC合并隐匿性CNV患者的临床管理和预后评估提供了重要见解,突出了多模态成像在评估治疗结果方面的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/404a1f742fcd/fmed-12-1550543-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/dfb9d110c65f/fmed-12-1550543-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/7432c0cf183e/fmed-12-1550543-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/c48c1bb1abda/fmed-12-1550543-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/404a1f742fcd/fmed-12-1550543-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/dfb9d110c65f/fmed-12-1550543-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/7432c0cf183e/fmed-12-1550543-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/c48c1bb1abda/fmed-12-1550543-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c689/11975556/404a1f742fcd/fmed-12-1550543-g004.jpg

相似文献

[1]
Intravitreal conbercept for chronic central serous chorioretinopathy with occult CNV: a retrospective clinical study based on multimodal ophthalmic imaging.

Front Med (Lausanne). 2025-3-25

[2]
Choroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy.

Biomedicines. 2024-12-3

[3]
Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy.

Int J Ophthalmol. 2021-5-18

[4]
Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization.

BMC Ophthalmol. 2024-2-19

[5]
Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization.

PLoS One. 2023

[6]
The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy.

J Ophthalmol. 2019-5-7

[7]
Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.

Br J Ophthalmol. 2020-7

[8]
Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy.

Br J Ophthalmol. 2020-11

[9]
RETROSPECTIVE ANALYSIS OF THE PRESENCE OF CHOROIDAL NEOVASCULARISATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY WITH THE AID OF PHOTODYNAMIC THERAPY.

Cesk Slov Oftalmol. 2021

[10]
FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.

Retina. 2017-10

本文引用的文献

[1]
Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration.

Sci Rep. 2024-5-25

[2]
Central Serous Chorioretinopathy: Epidemiology, Genetics and Clinical Features.

Annu Rev Vis Sci. 2024-9

[3]
Clinical Landscape of Central Serous Chorioretinopathy in Germany: Retina.net CSC Registry Report Number 1.

Ophthalmologica. 2024

[4]
Central serous chorioretinopathy: An evidence-based treatment guideline.

Prog Retin Eye Res. 2024-7

[5]
The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2024-5

[6]
Clinical efficacy of conbercept injection on neovascular age-related macular degeneration under different levels of inflammation.

Adv Clin Exp Med. 2024-4

[7]
Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

Diagnostics (Basel). 2023-8-29

[8]
Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies.

Eye Vis (Lond). 2023-7-11

[9]
Central Serous Chorioretinopathy by Autofluorescence, Enface and SLO-Retromode Imaging.

Life (Basel). 2023-6-17

[10]
Characteristics and Classification of Choroidal Caverns in Patients with Various Retinal and Chorioretinal Diseases.

J Clin Med. 2022-11-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索